By VETTAPHARMA reporter – Derek Roche: Biocon Limited announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Liraglutide Injection (gSaxenda®), a chronic weight-management drug, marking a major regulatory milestone for the Indian biopharmaceutical company.
The approved product is an 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen formulation indicated as an adjunct to a reduced-calorie diet and increased physical activity for treating chronic weight management.
Biocon’s Chief Executive Officer and Managing Director, Siddharth Mittal, described the approval as a “defining milestone”, validating the company’s scientific capabilities and vertically integrated development and manufacturing platform. The company said it is committed to commercializing Liraglutide (gSaxenda®) rapidly to ensure access to a high-quality, affordable treatment option for patients in the United States.
The U.S. addressable market opportunity for GLP-1 receptor agonists—the therapeutic class that includes Liraglutide—was valued at approximately US $127 million according to IQVIA MAT December 2025 data, reflecting the growing demand for obesity and weight-management therapies.
Liraglutide itself is a synthetic analog of the glucagon-like peptide-1 (GLP-1) peptide and has a long regulatory history: it was first approved for medical use in the European Union in 2009 and in the United States in 2010 for diabetes treatment, with subsequent approvals for weight management indications in later years.
This approval places Biocon among global competitors in the weight-management drug arena, underscoring the company’s expanding role in high-growth therapeutic segments such as obesity and metabolic disorders.
